LOL. Doesn't anyone see an issue with a sector raising so much cash for a 10% possibility of success? Shouldn't they rethink public funding of experimental medicine? What's it say about a system where executives become millionaires even as their companies fail ninety percent of the time? Hmm
>>Biotechs are an easy target of the short mafia because 90% of all biotechs fail. That means that there is a 90% chance they are right if they bet it goes down. Pharma companies are in constant need of capital and that pressure to raise money almost always seems to lag the rate of development.
So when a short biotech analyst boasts about his track record of shorting you really have to take that with a grain of salt.
He is toast...."Stat News reporter, Adam Feuerstein is believed by many to be the ring leader as he is known as “the most feared man in biotech.” He is however losing his relevance as he resorts to cyberbullying instead of actual analysis. Many of his pans are on the verge of approval. In fact 3 of Feuerensteins fab five could see approval in short order. "